Aislinn Antrim, Associate Editorial Director

Pharmacists can play a crucial role in educating parents and helping remind them about the childhood vaccine schedule, which can be quite complex.

Results from the VALOR-HCM LTE trial at 56 weeks demonstrated that with longer follow-up, mavacamten continued to reduce patient eligibility for invasive septal reduction therapy.

When children got less than the recommended 9 hours of sleep or took more than 30 minutes to fall asleep, there was a strong link to impulsive behaviors later in life.

Participants indicated that they would be more likely to accept PrEP-related information if it was recommended by a trusted person.

Notably, 65% of the participants experiencing pain at the 2-month follow up were also experiencing pain at their 12-month follow up, suggesting persistent and long-term pain.

Relapses of MIS-C occurred in 2 patients due to rapid tapering of corticosteroids at 2 weeks instead of the standard protocol of 4 to 6 weeks.

Sleep loss is known to impact key processes such as attention, cognition, learning, memory, metabolism, and immune function.

Based on results from a trial of repotrectinib in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer, the FDA accepted the New Drug Application and set a Prescription Drug User Fee Act goal date of November 27, 2023.

The approach allows investigators to assess post-vaccine response in immunocompromised patients who have received antibody prophylaxis.

The program would aim to incentivize competition in small molecule generics markets, which currently have limited competition.

However, the FDA said an application for zuranolone to treat major depressive disorder did not provide substantial evidence of efficacy.

Study notes that consumers should look for plant-based milk alternative products that list calcium and vitamin D as ingredients.

The prolonged lack of viral exposure has likely increased the pool of children and adults vulnerable to respiratory syncytial virus, but questions remain.

The approval marks the first monoclonal antibody approved to protect all infants through their first respiratory syncytial virus season.

The approval makes remdesivir the first and only approved antiviral treatment for patients across all stages of renal disease.

Express Scripts recently announced the addition of 3 Humira biosimilars to its main formulary.

The approval of norgestrel tablets (Opill) could open the door to other prescription-to-OTC contraceptive switches, although that remains to be seen as other pharmaceutical companies weigh their options.

Study shows equivalent overall survival among younger adults with acute lymphoblastic leukemia aged 15 to 29 and older adults aged 30 to 50 with normal BMI.

Using artificial intelligence to sort and respond to patient queries could streamline processes and alleviate provider burnout.

The study also found significant evidence of outcomes disparities between minority populations and White populations.

Less than half of respondents would recommend a vaccine against respiratory syncytial virus to a pregnant friend or family member.

Body mass index fails to account for differences in race, ethnicity, age, sex, and other factors, and has a history of use for racist exclusion.

Several workplace risk factors, including safety concerns going unaddressed, predicted suicidal thoughts.

Clinical trial results showed that the combination significantly improved radiographic progression-free survival compared with enzalutamide monotherapy for homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.

A plethora of targeted therapies, biomarker-driven therapies, and immunotherapies are now available.

The meeting aims to bring together pharmacists to discuss solutions for responding to the rapidly evolving evidence and needs for effective implementation.

Having more severe sleep apneas was associated with having lower brain volume in the medial temporal lobe area of the brain, which could suggest loss of brain cells.

The combination also reduced the risk of developing distant metastasis or death by 65% in patients with high-risk stage 3/4 melanoma.

The proportion of participants with cytomegalovirus disease was 10% with letermovir and 12% with valganciclovir.

Findings highlight the potential efficacy of combining 2 novel bispecific therapies, teclistamab-cqyv and talquetamab, which target distinct antigens on myeloma cells.